AIHTA - Publications - Search - Items where Subject is "WJ 700-875 Male genitalia"
Number of items at this level: 37.

Adlbrecht, C. and Wild, C. (2007): [Photoselective vaporisation of the prostate in men with benign prostatic hyperplasia. HTA in hospitals]. Decision Support Document 01.

Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.

Breuer, J. and Nachtnebel, A. (2013): Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy . DSD: Horizon Scanning in Oncology 37.

Erdos, J. and Formoso, G. and Djuric, O. and Bonvicini, L. and Pezzarossi, A. and Ballini, L. and Jeroncic, A. (2021): Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia – German Summary of the EUnetHTA OCTA27 Assessment. Decision Support Document 129.

Erdos, J. and Fischer, S. (2018): High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018. Decision Support Document 37/ Update 2018.

Fischer, S. and Kisser, A. (2015): Robot-assisted surgery: A systematic review of effectiveness and safety for elected indications and accumulating costs. HTA-Projektbericht 84.

Geiger-Gritsch, S. (2008): [Testosterone-substitution for androgen deficiency in the ageing men]. HTA-Newsletter 66: p. 2.

Grössmann, N. (2021): Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Update August 2021. Oncology Fact Sheet Nr. 46.

Grössmann, N. (2021): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Update February 2021. Oncology Fact Sheet Nr. 8.

Grössmann, N. (2021): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Update February 2021. Oncology Fact Sheet Nr. 23.

Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Update July 2020. Oncology Fact Sheet Nr. 2.

Mad, P. (2007): [Robotic surgery in urology: Prostate interventions]. HTA-Newsletter 54: p. 4.

Mathis, S. (2007): [Interstitial brachytherapy in the treatment of localised prostate cancer]. HTA-Newsletter 57: p. 4.

Nachtnebel, A. (2011): Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer. DSD: Horizon Scanning in Oncology 16.

Nachtnebel, A. and Püntmann, I. (2011): Abiraterone acetate (Zytiga™) as 2nd-line therapy for the treatment of metastatic castration resistant prostate cancer after docetaxel therapy. DSD: Horizon Scanning in Oncology 20.

Riegelnegg, M. and Gassner, L. and Grössmann-Waniek, N. (2023): Robot-assisted surgery in thoracic and visceral indications – Update 2023. HTA-Projektbericht 108/ Update 2023.

Rothschedl, E. and Grössmann, N. (2023): Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Fact Sheet Nr. 161.

Rothschedl, E. and Wolf, S. (2023): Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer. Update October 2023. Fact Sheet Nr. 134.

Rothschedl, E. and Wolf, S. (2023): Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update July 2023. Fact Sheet Nr. 125.

Rothschedl, E. and Wolf, S. (2023): Olaparib (Lynparza®) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 117.

Rothschedl, E. and Wolf, S. (2023): Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone‑sensitive prostate cancer (mHSPC). Update June 2023. Fact Sheet Nr. 123.

Rothschedl, E. and Wolf, S. (2022): Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 114.

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer. Oncology Fact Sheet Nr. 65.

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) for treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. Oncology Fact Sheet Nr. 66.

Rothschedl, E. and Wolf, S. (2022): Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update November 2022. Oncology Fact Sheet Nr. 80.

Rothschedl, E. (2019): Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90.

Rothschedl, E. (2019): Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88.

Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.

Schmidt, L. and Lohr, P. and Wild, C. (2018): Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107.

Stanak, M. and Grössmann, N. and Strohmaier, C. (2019): 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118.

Vreugdenburg, Thomas and Wild, C. (2017): Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105.

Warmuth, M. and Johansson, T. (2010): High-intensity focussed ultrasound (HIFU) for the treatment of prostate cancer. Decision Support Document 37.

Wild, C. (2003): [Cryosurgery for prostate cancer]. HTA-Newsletter 23: p. 2.

Wild, C. (2001): [Brachytherapy for prostate cancer]. HTA-Newsletter 02: p. 3.

Wild, C. and Adlbrecht, C. (2007): [Laser vaporisation of benign prostatic hyperplasia]. HTA-Newsletter 56: p. 2.

Wolf, S. and Al Froukh, R.F. (2023): 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review. 1st Update 2023. Decision Support Document 118/ Update 2023.

Wolf, S. and Grössmann, N. (2020): Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble). Decision Support Document 123.

This list was generated on Thu Mar 28 20:00:09 2024 CET.